Market Introduction
Drug delivery systems are the technologies primarily used for the controlled or targeted delivery of various therapeutic agents to treat various diseases or improve the health of the patients. Nasal drug delivery is one of the efficient routes of drug administration. It offers needle-free drug delivery, optimal route for brain-targeted therapies, and superior bioavailability. Nasal route of administration is preferred in several disease indications such as Parkinson’s disease, prostate cancer, migraine, and influenza amongst others. Moreover, nasal route is also suitable for the treatment of drug addiction as well as for sedation.
Market Overview and Dynamics
The Asia Pacific nasal delivery devices market is expected to reach US$ 21,402.86 million in 2027 from US$ 12,418.34 million in 2019. The market is estimated to grow with a CAGR of 7.1% from 2020-2027. The growth of the market is attributed to some key driving factors such as the increasing development in healthcare infrastructure and the growing prevalence of diseases of central nervous system. However, the market growth is likely to be hindered owing to the issues regarding nasal delivery devices market.
Key Market Segments
Based on drug type, the nasal delivery devices market is anaesthetics, antibiotics, pain relief drugs, calcium supplements, vasoconstrictors, antihistamines, and others. Based on delivery technologies, the nasal delivery devices market, is segmented into spray, nebulizers, inhalers, and others. Based on end user, the nasal delivery devices market, is segmented into home care settings, hospitals, and clinics.
Major Sources and Companies Listed
Some of the major primary and secondary sources for nasal delivery devices market included in the report are Organization for Economic Co-operation and Development (OECD), Alzheimer’s and Related Disorders Society of India (ARDSI), and others.
Reasons to buy the report
- To understand the Asia Pacific nasal delivery devices market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for nasal delivery devices market
- Efficiently plan M&A and partnership deals in Asia Pacific nasal delivery devices market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Nasal delivery devices market
- Obtain market revenue forecast for market by various segments from 2019 to 2027 in Asia Pacific region
ASIA PACIFIC NASAL DELIVERY DEVICES MARKET SEGMENTATION
- Anaesthetics
- Antibiotics
- Pain Relief Drugs
- Calcium Supplements
- Vasoconstrictors
- Antihistamines
- Others
- Spray
- Nebulizers
- Inhalers
- Others
- Home Care Settings
- Hospitals
- Clinics
By Country
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia Pacific
Company Profiles
- GlaxoSmithKline plc.
- AstraZeneca
- Pfizer Inc.
- BD
- Sanofi
- Merck & Co., Inc.
- Cadila Pharmaceuticals Ltd.
- Novartis AG
- Dr. Reddy's Laboratories
Asia Pacific Nasal Delivery Devices Market Strategic Insights
Asia Pacific Nasal Delivery Devices Market Report Highlights
| Report Attribute | Details |
| Market size in 2019 | US$ 12,418.34 Million |
| Market Size by 2027 | US$ 21,402.86 Million |
| CAGR (2020 - 2027) | 7.1% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Drug Type
|
|
Regions and Countries Covered
|
|
| Asia-Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
Asia Pacific Nasal Delivery Devices Market Country and Regional Insights
